An Australian study published in the journal Supportive Care in Cancer has revealed that levels of physical activity decline after patients are diagnosed with myeloma. The research surveyed 229 myeloma patients and found that participation in physical activity declined significantly from pre-diagnosis levels. Fatigue, injuries and pain were identified as the strongest perceived barriers to taking part. However, 41% of patients were willing to try an exercise programme if one was offered to them.
The 54th Annual Meeting of the American Society of Haematology (ASH) took place on the 8 – 12 December inAtlanta,USA. This year, some 200 talks and over 500 posters dedicated to myeloma research were presented. Here, we summarise some of the highlights emerging from the conference:
The latest results from an international Phase III clinical study, show that pomalidomide with low-dose dexamethasone improves the length of remission and extends overall survival in relapsed and refractory myeloma patients. Pomalidomide, an immunomodulatory drug (IMiD) similar to Revlimid® and derived from thalidomide, is being developed by the pharmaceutical company Celgene as a potential treatment in myeloma.